P
atients with hypertrophic cardiomyopathy (HCM) have coronary artery dysfunction characterized by thickened walls with increased intimal and medial collagen. 1 These alterations in the architecture of the coronary microvasculature result in reduced coronary flow reserve and contribute to adverse left ventricular (LV) remodeling, myocardial ischemia, replacement scarring/ fibrosis, systolic dysfunction and serve as arrhythmogenic substrate for electrical instability and sudden cardiac death. 1 Historically, much of this coronary vascular dysfunction has been ascribed to a mismatch between myocardial mass and coronary perfusion, and as such, relegated as secondary to the cardiac phenotype. 1 However, emerging evidence suggests that defects in vasomotor function are not localized to the coronary arteries.
Exposure of the vasculature to nitroglycerin produces nearmaximal vasodilation as a result of smooth muscle relaxation. This measure is also an independent predictor of future cardiovascular events, irrespective of the presence of atherosclerosis. 2 While it has been demonstrated that the coronary smooth muscle function may be impaired in HCM, 3 information on peripheral vascular smooth muscle function is lacking. 4 In the current issue, Bartolomucci and colleagues examined the vasomotor response of the brachial artery to sublingual nitroglycerine in patients with HCM compared to non-HCM controls and non-HCM controls with hypertensive LV hypertrophy. 5 Patients with HCM had a blunted response, suggestive of a primary defect in peripheral conduit vessel smooth muscle vasomotor function. These findings provide important exculpatory evidence that vascular dysfunction in HCM is systemic.
An attractive hypothesis put forth by the authors to explain noted smooth muscle dysfunction relates to modulation of vascular structure. Patients with HCM have increased arterial stiffness and this is more pronounced in HCM patients with myocardial fibrosis. 6 Indeed, factors that govern myocardial collagen accumulation/fibrosis also contribute to arterial fibrosis, with the latter contributing to increased arterial stiffness. 7 Bartolomucci et al. state that increased arterial stiffness may limit maximal vasodilatory capacity of the brachial artery in HCM. Reappraisal of results provides additional insight in support of this hypothesis. The β-stiffness index is a pressureindependent measure of arterial stiffness that can be derived from arterial pressure and diameter measures as follows: (ln systolic blood pressure/diastolic blood pressure)/((end-systolic diameter−end-diastolic diameter)/end-diastolic diameter). Calculating β-stiffness index of the brachial artery from mean values 5 demonstrates higher arterial stiffness in HCM patients (8.9 units) vs. hypertensive controls (8.4 units) and normotensive controls (6.5 units).
The brachial vascular response to incremental doses of vasoactive medications is complex. Initial smooth muscle relaxation reduces arterial stiffness by decreasing tension in the smooth muscle itself and in its associated series elastic component. 8 However, near-maximal relaxation may increase arterial stiffness by increasing arterial size and transposing stress away from elastin fibers, tensing the collagen jacket (i.e., alteration of the fractional recruitment of collagen via engagement of stiff collagen fibers that were previously slack). 8 There is ample anatomical evidence to suggest that smooth muscle is surrounded by a meshwork of collagen. Thus, collagen deposition/fibrosis may alter systemic vascular architecture and increase arterial stiffness in HCM, modulating the interaction of elastin, collagen, and smooth muscle in response to changes in vessel wall stress-strain.
It is becoming apparent that the ramifications of HCM extend beyond the hypertrophied heart. The current work of Bartolomucci et al. builds nicely upon an ever-growing body of literature demonstrating that HCM is truly a cardiovascular disease.
Disclosure: The author declared no conflict of interest.
